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Abstract 
Current treatment of diabetic nephropathy is effective; however, substantial gaps in care still 
remain and new therapies are urgently needed to reduce the global burden of the complication. 
Desirable properties of an “ideal” new drug should include: primary prevention of 
microalbuminuria, additive/synergistic anti-proteinuric effect in combination therapy with renin 
angiotensin system blockers, reduction of chronic kidney disease progression to lower the risk of 
end-stage renal disease, and cardiovascular protection. Growing evidence suggests that sodium-
glucose cotransporter 2 inhibitors (SGLT2i) may fulfill many of these criteria and represent novel 
tools to cover the unmet needs in diabetic nephropathy care. However, the underlying mechanisms 
of SGLT2i renal benefits are still poorly understood and promising results from cardiovascular 
outcome trials with SGLT2i need confirmation in dedicated renal outcome trials. 
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Diabetic nephropathy (DN) affects nearly half of patients with type 2 diabetes and is characterized 
by albuminuria and/or relentless decline in renal function. Today, DN is the leading cause of End 
Stage Renal Disease (ESRD) in the Western World. In addition, the development of DN enhances 
the risk of cardiovascular (CV) morbidity and mortality. Subjects who have both diabetes and DN 
have a 3-12-fold higher risk of mortality than those with diabetes only, and most of them will die 
before ESRD development, predominantly of CV diseases1-3. 
In the nineties landmark intervention studies proved the efficacy of blockade of the renin 
angiotensin system (RAS) with either ACE inhibitors (ACE-I) or angiotensin II receptor 
antagonists (ARB) in reducing progression of both albuminuria and renal function loss4-7. Since 
then no drug was licensed for DN treatment despite intensive research to identify new therapeutic 
strategies. Our understanding of the cellular and molecular mechanisms of DN has significantly 
improved in the last decades; however, promising preclinical compounds failed to show efficacy 
in humans. Recently, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have come on the scene 
as potential drug candidates for DN. Herein, we will review recent data, supporting the hypothesis 
that SGLT2i may be a novel tool to address the unmet need for renal protection in patients with 
diabetes. Moreover, we will discuss potential underlying mechanisms. 
 
The Unmet Needs in Diabetic Nephropathy Care 
The first clinical sign of DN is a moderately increased urinary albumin excretion (UACR 30-300 
mg/g), formerly named microalbuminuria. Intensive glucose control reduces the risk of 
microalbuminuria in patients with both type 1 (DM1) and type 2 diabetes (DM2). In the 
BENEDICT (The BErgamo NEphrologic DIabetes Complications Trial) study, treatment with 
ACE-I prevented microalbuminuria in hypertensive DM28, but this was not confirmed in either 
normotensive DM1 patients treated with an ACE-I9 or hypertensive DM2 patients treated with an 
ARB10. Therefore, prevention of microalbuminuria is so far solely based on blood glucose control.  
Progression from micro to macroalbuminuria (UACR >300 mg/g) characteristically occurs over a 
period of years and is affected by intervention, most notably reduction of blood pressure and RAS 
inhibition. Both ACE-I and ARB reduce albuminuria progression and even induce regression of 
microalbuminuria to normoalbuminuria. Although these drugs have changed the natural history of 
DN, a residual risk still remains and around 30% patients progress to macroalbuminuria despite 
optimum treatment11.  
Regardless of the presence of albuminuria, diabetic kidney disease is characterized by a 
progressive renal function loss that may lead to ESRD or renal death. Both blood glucose control 
and RAS blockade can slow the glomerular filtration rate (GFR) decline; however, their efficacy 
in reducing the risk of long-term renal outcomes is modest compared to that on albuminuria12. This 
may partially explain why in the last thirty years albuminuria prevalence has diminished, while 
that of advanced chronic kidney disease (CKD) has increased three-fold, making non-albuminuric 
DN the prevailing phenotype1. Besides renal outcomes, worsening of DN progressively increases 
the CV risk13. The non-albuminuric phenotype is also associated with higher mortality risk and the 
presence of both albuminuria and CKD has a synergistic effect14. A multifactorial intervention 
targeting not only diabetes, but also CV risk factors is beneficial in reducing both all cause and 
CV mortality, but insufficient to abolish the enhanced CV risk associated with DN15. 
Taken together these data indicate that current treatment of DN with anti-hyperglycemic drugs, 
blood pressure lowering agents, and RAS blockers is effective, but substantial gaps in care still 
remain. Desirable properties of an “ideal” new drug for DN therapy should include: (i) prevention 
of microalbuminuria, (ii) an additive/synergistic effect in combination with RAS blockers on 
albuminuria, (iii) marked reduction of CKD progression to prevent long-term major renal events, 
and (iv) cardio-protection. 
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SGLT2 
SGLT2 is a high-capacity low affinity sodium glucose co-transporter, present on the luminal 
surface of proximal tubule (PT) cells. SGLT2 is responsible for the majority of tubular glucose 
reabsorption (80-90% of filtered glucose). The residual 10-20% is reabsorbed by SGLT1, a low-
capacity high-affinity co-transporter, exposed on the distal part of the PT. Entry of sodium and 
glucose within tubular cells via SGLT1/2 follows a sodium gradient generated by a Na-K-ATPase 
pump. After reabsorption, glucose moves passively into the interstitium using the facilitative 
glucose transporters GLUT1 and GLUT2, which are expressed on the basolateral membrane of PT 
cells16,17. 
 
Glycemic and extra-glycemic effects of SGLT2 inhibitors  
Data on the tubular expression of SGLT2 and SGLT1 in human DM2 are conflicting18,19,20. 
However, the maximal glucose reabsorption capacity of the kidney is increased in DM2 and this 
contributes to hyperglycemia, providing a rationale for SGLT2 inhibition21. Treatment with 
SGLT2i can improve glucose control in DM2 by reducing renal glucose reabsorption and today 
the SGLT2i canagliflozin, dapagliflozin, empagliflozin, and ertuglifozin are widely used in DM2 
therapy, while ipragliflozin, luseogliflozin, and tofogliflozin are available in Japan only.  
Hyperglycemia is a well-established risk factor for DN both onset and progression; however, 
SGLT2i are not recommended in DM2 patients with reduced renal function because of their 
diminished anti-hyperglycemic effect in people with low eGFR21. Indeed, the primary determinant 
of tubular glucose reabsorption (or loss in the presence of SGLT2i) is the amount of filtered 
glucose that depends not only on blood glucose levels, but also on renal function21.  
Besides lowering blood glucose, SGLT2i also reduce both body weight22 and uric acid (UA) levels. 
SGLT2i-induced glycosuria diminishes weight through calorie loss. GLUT9 exchanges glucose 
for UA and has been implicated in the uricosuric effect of SGLT2 inhibition23,24. However, recent 
evidence in experimental animals indicates that GLUT9 is dispensable, while URAT1 is required 
for the uricosuric response to SGLT2i25. Inhibition of URAT1-mediated UA tubular reabsorption 
by glycosuria is considered the predominant mechanism. In addition, as insulin induces URAT1 
expression, SGLT2i may also enhance uricosuria by ameliorating glucose control and thus 
suppressing insulin25. 
Treatment with SGLT2i also lowers blood pressure (BP) without a compensatory increase in heart 
rate26. In a meta-analysis of 22,528 patients from 43 RCTs, mean difference in systolic and 
diastolic BP between SGLT2i and placebo/comparators were -2.46 and -1.46 mm Hg, 
respectively27. Enhanced natriuresis and osmotic diuresis, leading to sustained reduction in plasma 
volume, as well as reduced sympathetic tone and arterial stiffness have been proposed as 
underlying mechanisms26,28. At variance with the anti-hyperglycemic effect, the BP lowering 
activity of SGLT2i is preserved and even enhanced in advancing CKD29. The underlying 
mechanism is unclear; however, patients with CKD are more salt sensitive and the natriuretic 
effect of SGLT2i may thus result in more pronounced BP diminution in these subjects26,28. This 
anti-hypertensive effect is highly relevant in the context of DN as BP control is challenging in 
patients with CKD and hypertension plays a key role in both albuminuria and CKD progression. 
 
SGLT2 inhibition and cardiovascular outcomes 
Since 2008 the Food and Drug Administration (FDA) required new diabetes drugs intended to 
ameliorate glycemic control to also show CV safety. The CV outcome trials (CVOT) EMPA-REG 
OUTCOME and CANVAS Program reported a reduced risk of major advanced cardiovascular 
events (MACE 3-points: CV mortality, non-fatal myocardial infarction, or non-fatal stroke) in 
SGLT2i-treated patients, though the striking reduction in CV death observed with empagliflozin 
was not seen with canagliflozin30,31. In contrast the DECLARE-TIMI 58 trial only proved non-
inferiority of dapagliflozin compared to placebo with respect to MACE32 (Table 1). Likely, results 
varied among trials because of differences in the CV risk of recruited subjects as EMPA-REG 
enrolled exclusively patients with established CV diseases, while CANVAS and DECLARE also 
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included subjects in primary prevention. Consistent with this, a recent meta-analysis has showed 
that SGLT2i reduced the risk of MACE solely in DM2 patients in secondary CV prevention33. An 
important additional finding of these CVOT was a 23% reduced risk of hospitalization for heart 
failure (HF) in SGLT2i-treated patients that was consistent across trails regardless of baseline CV 
risk category and history of HF30,31,32,33. This effect was even greater in patients with reduced renal 
function, suggesting a specific cardiac benefit in patients with DN33. 
 
Renal effects of SGLT-2 inhibition  
CVOT with SGLT2i also included secondary renal outcomes, though definitions of renal 
endpoints slightly varied among trials, making direct comparisons difficult. In the next paragraphs 
we will discuss whether available data support the hypothesis that SGLT2i may cover the specific 
unmet needs in DN care described above.  
 
Prevention of Microalbuminuria and SGLT2i 
Data on the efficacy of SGLT2i in preventing new onset microalbuminuria are conflicting with a 
20% risk reduction in CANVAS34 and no effect in EMPA-REG35. However, EMPA-REG findings 
were based on a single UACR measurement and a subsequent analysis using confirmed UACR 
data, reported a lower risk of new micro/macroalbuminuria onset in patients with baseline 
normoalbuminuria36. Moreover, placebo-adjusted UACR was significantly reduced in patients 
with baseline normoalbuminuria in both trials34,36. The effect was, however, modest (EMPA-REG 
OUTCOME -9%, CANVAS -12%) and difficult to interpret because of the high inherent 
variability of UACR measurements. In addition, the UACR reduction was no longer present after 
cessation of treatment in the EMPA-REG, suggesting a transient hemodynamic underlying 
mechanism36 (Figure 1). 
 
Progression and Regression of Albuminuria and SGLT2i 
In CVOT with SGLT2i, treatment with empagliflozin and canagliflozin reduced the risk of new 
onset macroalbuminuria by 40% and the shift to higher albuminuria category 
by 30%, indicating efficacy of SGLT2 inhibition in reducing 
albuminuria progression. Moreover, SGLT2 inhibition also enhanced 
the likelihood of albuminuria regression by 60-70%31,34,35,36 (Figure 1). 
In agreement with these data, analyses treating UACR as a continuous variable showed that 
placebo-adjusted UACR was significantly reduced in patients with either microalbuminuria 
(EMPA-REG -30% and CANVAS -34%) or macroalbuminuria (EMPA-REG -32% and CANVAS 
-36%)34,35,36.  
The magnitude of these changes in albuminuria is clinically relevant and comparable to that of 
RAS inhibitors. Furthermore, most patients (80%) were already on RAS 
blockers, suggesting a benefit of adding SGLT2i to current therapy. In 
addition, the reduction in UACR was consistent across eGFR strata and 
dapagliflozin also displayed anti-proteinuric properties in DM2 
patients with stage 3-4 CKD37,38. 
Therefore, treatment with SGLT2i may be a valuable approach for providing greater reduction in 
albuminuria and ultimately renoprotection. Whether micro/macroalbuminuria is solely a 
biomarker or a surrogate end-point for renal outcomes is still matter of debate; however, a meta-
analysis of large clinical trials suggested that a 30% decline in albuminuria, as reported in CVOT 
with SGLT2i, might translate in a 24% ESRD risk reduction, assuming that risk factors and other 
biomarkers are unchanged39. 
The underlying mechanism of the SGLT2i anti-proteinuric effect is unknown. However, in the 
EMPA-REG, reduction of UACR in patients with albuminuria persisted, at least in part, after 
cessation of treatment36, implying that SGLT2 inhibition may reduce the glomerular injury leading 
to albuminuria (see below the section on mechanisms). 
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Progressive CKD and SGLT2i 
Findings from CVOT suggest that SGLT2i may also slow CKD progression and reduce occurrence 
of renal events of clinical relevance to patients, as renal replacement therapy (RRT) and renal 
death, and this has generated considerable enthusiasm (Figure 2). In a post-hoc analysis of the 
EMPA-REG, treatment with empagliflozin was associated with a significant 46% risk reduction 
of a composite of doubling of serum creatinine (44% risk reduction), initiation of RRT (55% risk 
reduction), and renal death35. Although renal end-points were not confirmed or adjudicated in the 
trial, results were similar using retrospectively confirmed events, though the effect on RRT was 
no longer significant40. 
In CANVAS patients treated with canagliflozin had a 40% risk reduction of a pre-specified 
composite of sustained 40% eGFR reduction, ESRD, or renal death. Replacing the 40% eGFR 
decline with doubling of serum creatinine (57% eGFR decline) did not change the result31,34. 
However, only a numerical trend for reduced RRT risk was observed during the relatively short 
follow-up. The DECLARE trial reported a 47% risk reduction of a similar composite renal 
outcome in patients treated with dapagliflozin, thought the effect on the individual components of 
the composite was not reported32. 
Overall these results look very promising; however, results were driven predominantly by changes 
in eGFR rather that by hard renal outcomes and the number of subjects developing ESRD, the 
most important clinical outcome for CKD progression, was small (27 events in EMPA-REG and 
21 in CANVAS). Moreover, analyses were deemed exploratory and not formally statistically 
significant in CANVAS and DECLARE because of the pre-specified hierarchical testing plan. 
Therefore, these data need to be interpreted with caution and they are meant to generate hypotheses 
rather than to prove efficacy. Nevertheless robustness of findings is suggested by the magnitude 
of the differences between SGLT2i and placebo and the consistency of results across both renal 
endpoints and trials. In line with this, SGLT2i therapy strongly reduced the composite outcome of 
worsening of renal function, ESRD, or renal death by 45% in the meta-analysis of these trials33. 
Moreover, renoprotection was the strongest and more consistent effect of SGLT2i and it was 
equally robust in patients with and without CV disease33. 
Most patients in CVOT with SGLT2i had normal baseline renal function because an eGFR below 
30-60 ml/min/1.73 m2 was an exclusion criterion. In addition, mean eGFR levels at follow-up were 
still in the normal range, though significantly different between groups. This raises the question 
whether SGLT2i are also effective in patients with established CKD. Subgroup analyses did not 
show difference in renal outcomes across eGFR categories down to 30 ml/min/1.73m2 34,35,41-43, 
but the meta-analysis found a lesser reduction in CKD progression in patients with worse baseline 
renal function33. Data from ongoing SGLT2i trials focusing on patients with established CKD will 
clarify this relevant point.  
On the other hand, the finding that SGLT2 inhibition can slow eGFR decline prior to CKD 
development may be important as studies in both DM1 and DM2 suggest that the rate of early 
(before CKD development) eGFR decline is a predictor of renal outcomes44,45. Therefore, 
changing the slope of early eGFR decline with SGLT2i may be a primary prevention strategy to 
delay CKD onset and delay/avoid renal events. Of interest, the difference in eGFR slopes between 
empagliflozin and placebo was greater in patients with macroalbuminuria and/or hypertension43, 
suggesting that SGLT2i may be particularly effective in stabilizing renal function in these high-
risk subgroups.  
 
Mechanisms of SGLT2i effect in the kidney 
 
The underlying mechanism/s whereby SGLT2i exert their anti-proteinuric and renoprotective 
effects are still unclear and in the following paragraphs we will summarize the main current 
hypotheses (Figure 3). 
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Beneficial effects on risk factors  
In CVOT trials, body weight and both HbA1c and BP levels were lower in SGLT2i- than in 
placebo-treated patients. However, the effect on both HbA1c (0.5%) and body weight 
(1.7Kg) was modest. Canagliflozin slowed progression of renal 
function decline compared to glimepiride in the CANTATA-SU study 
despite similar HbA1c levels in the two arms of the study46. Moreover, 
adjustment for changes in these variables did not modify the results 
on various renal end-points34,36,37, making unlikely the possibility that the renal benefit 
of SGLT2i is fully explained by their positive effects on DN risk factors. 
 
The hemodynamic hypothesis 
Diabetes induces glomerular capillary hypertension and hyperfiltration. The greater efficacy of 
RAS blockers as compared to other BP lowering agents in their anti-proteinuric and renoprotective 
action has been ascribed to their capacity to reduce glomerular capillary pressure by removing the 
constrictor effect of angiotensin II on the efferent arteriole. According to the hemodynamic 
hypothesis, SGLT2i also reduce glomerular capillary pressure, but at variance with RAS blockers 
they act on the afferent arteriole by restoring the tubule-glomerular feedback (TGF). 
In diabetes hyperglycemia increases SGLT2-mediated tubular reabsorption of glucose and sodium 
and thus diminishes sodium delivery to the macula densa, mimicking kidney hypo-perfusion. In 
macula densa cells, lower sodium entry reduces basolateral release of adenosine, a potent 
vasoconstrictor, and thus causes afferent arteriolar vasodilation47. This leads to an enhanced 
glomerular capillary pressure and also allows transmission of any rise in systemic BP to the 
glomerular capillaries48. Inhibition of SGLT2 induces opposing effects, resulting in afferent 
arteriolar vasoconstriction and reduction of both intraglomerular pressure and glomerular 
filtration47. 
In keeping with this hypothesis, hyperfiltration is reduced in streptozotocin-induced diabetic mice 
knockout for SGLT249 and a study performed in patients with DM1 and hyperfiltration has 
demonstrated that empagliflozin attenuates diabetes-induced changes in renal hemodynamics, 
leading to glomerular hyperfiltration50. 
Changes in eGFR over time in CVOT with SGLT2i are also consistent with the hemodynamic 
hypothesis32,40. SGLT2i treatment causes an acute decline in eGFR during the first weeks of 
treatment likely due to a reduction in glomerular capillary pressure and thus glomerular filtration. 
This acute eGFR loss is a transient/reversible phenomenon as it is no longer present after SGLT2i 
discontinuation, and it is similar to that observed in response to RAS blockade. Following the 
initial drop, eGFR tends to return toward the baseline over several weeks, remaining stable 
thereafter, and at the end of the study is significantly higher than in placebo-treated patients, who 
show a gradual eGFR decline over time. Likely, the reduction in glomerular capillary pressure 
induced by SGLT2i protects glomerular cells from the hemodynamic insult with long-term 
advantageous effects. In keeping with this notion, an acute fall in eGFR induced by losartan 
predicted a less steep decline of renal function slope51. 
The underlying mechanisms are still unclear; however, glomeruli are highly compliant structures 
and an increase in glomerular capillary pressure results in glomerular volume expansion. Studies 
in isolated glomeruli have shown that as the intraglomerular pressure rises to levels similar to those 
seen in the diabetic kidney, glomerular volume increases by 30%52,53. Under normal conditions, 
renal auto-regulation allows tight control of intraglomerular pressure and glomeruli are exposed 
to small pulse pressure changes and their volume remains stable. By contrast, loss of auto-
regulation, as it occurs in the diabetic glomeruli, results in wide wings in glomerular volume up to 
18-fold changes52,53. In addition, at any given intraglomerular pressure level, larger hypertrophied 
glomeruli are more distensible than smaller glomeruli. Therefore, compensatory glomerular 
hypertrophy can magnify the deleterious effects of altered glomerular hemodynamics53. During 
glomerular expansion glomerular cells undergo centrifugal displacement and experience 
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substantial mechanical stretching and cyclic changes in glomerular volume are associated with 
repeated episodes of cell stretch and relaxation. 
Studies on glomerular cells exposed in vitro to mechanical stretching to mimic glomerular 
hypertension in vivo have shown that the mechanical insult can lead to changes in cell phenotype. 
Specifically, mesangial cells enhance production of extracellular matrix components and 
deleterious cytokines (MCP-1, TGF-1, VEGF), thus favoring sclerosis and inflammation54-56. In 
addition, they overexpress both GLUT-1 and the angiotensin AT1 receptor and this results in 
enhanced glucotoxicity and responsiveness to angiotensin II57,58. Furthermore, stretching of 
podocytes, which are crucial component of the glomerular filtration barrier, induces both nephrin 
downregulation59 and apoptosis60 that are key determinants in the pathogenesis of albuminuria.  
Glomerular capillary hypertension and hyperfiltration are a well-established mechanism of 
progression in all CKD. Whether SGLT2i may also be beneficial in other kidney diseases besides 
DN is undefined. Treatment with SGLT2i failed to show renoprotective effects in the 5/6 
nephrectomy animal model61 and in oxalate-induced CKD62, while a benefit was reported in a 
model of proteinuric non-diabetic nephropathy63. Recently, the TRANSLATE study has shown 
that short-term treatment with dapagliflozin did not modify renal hemodynamic function or 
attenuate proteinuria in either humans or in experimental focal segmental glomerulosclerosis 
(FSGS). SGLT2 expression was reduced in FSGS and the absence of diabetes-induced both 
hyperglycemia and SGLT2 overexpression/hyperactivity may explain the lack of efficacy64.  
 
Tubular Glucotoxicity  
Oxidative stress, inflammation, and fibrosis play a key role in the pathogenesis of DN. Studies in 
experimental DN have shown that SGLT2i ameliorate oxidative stress, inflammation, and fibrosis, 
predominantly in the tubule-interstitium, indicating a role of enhanced tubular glucose 
reabsorption through SGLT2 in their pathogenesis. However, available experimental data are 
highly heterogeneous, as different animal models, compounds, doses, and length of treatment were 
used, making difficult to draw final conclusions. In addition, many studies did not control for blood 
glucose and BP levels and it is difficult to distinguish between the direct beneficial effects of 
SGLT2i on the kidney and their indirect effect due to improved metabolism/hemodynamics. Table 
2 summarizes the study design and the results of the main studies on SGLT2i in experimental DN 
that control for blood glucose levels. 
 
The hypoxia hypothesis 
Diabetes increases oxygen requirement of the proximal tubules due to excessive glucose 
reabsorption by SGLT2. According with the hypothesis by Sano M et al, the resulting 
tubulointerstitial hypoxia causes trans-differentiation of EPO-producing interstitial fibroblasts in 
myofibroblasts, thus contributing to interstitial fibrosis. As trans-differentiation is reversible, 
treatment with SGLT2i can induce differentiation of myofibroblasts back to erythropoietin (EPO)-
producing cells, enhancing EPO production and more importantly limiting renal fibrosis65. In 
keeping with this notion, patients with DN are nearly twice as likely to develop anemia compared 
to patients with non-diabetic CKD and similar eGFR66. Moreover, treatment with SGLT2i 
increases both hematocrit values and EPO synthesis65,67,68.  
In experimental diabetes, inhibition of SGLT returned to normal renal cortex O2 tension, but 
worsened hypoxia in the medulla69. This likely reflects increased delivery of sodium to the distal 
nephron that enhances medullary transport and hence consumption of oxygen. Indeed, in the 
proximal tubule, SGLT2i not only inhibits SGLT2, but also Na+/H+ exchanger-3-dependent 
sodium uptake, preventing compensation of diminished Na+ reabsorption by SGLT70. This raises 
the hypothesis that the increased EPO production may be important in limiting the potential 
deleterious effects of SGLT2i-induced medullary hypoxia26. 
Moreover, in subjects treated with SGLT2i increased oxygen consumption in the medulla can also 
be balanced by a metabolic shift toward more energy-efficient fuels. According with the “thrifty 
substrate hypothesis”71, treatment with SGLT2i induces persistent hyperketonemia and tissues that 
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are more susceptible to hypoxia, as the renal medulla, can oxidize β-hydroxybutyrate instead of 
fatty acids. Compared to fatty acid, ketone bodies are more energetically efficient, yielding more 
energy available for ATP synthesis per molecule of oxygen. Therefore, this shift in substrate 
energetics may reduce the risk of hypoxia within the renal medulla. In addition, a rise in circulating 
β-hydroxybutyrate levels increases the acetylation of renal histones H3K9 and H3K14 that induce 
expression of genes promoting resistance to oxidative stress72. Therefore, SGLT2-i not only may 
prevent hypoxia, but also reduce the deleterious effects of hypoxia-induced oxidative stress. 
However, further studies are required to confirm these fascinating hypotheses.  
 
Alterative RAS pathways  
SGLT2i can induce RAS activation by enhancing both diuresis and natriuresis73. However, most 
patients enrolled in CVOT with SGLT2i were on RAS blockers and hence the classical renin-
angiotensin II-AT1 receptor pathway was blocked. In this context, angiotensin processing may 
occur via the ACE homolog ACE2, resulting in formation of Ang-(1-7) and Ang-(1-9), and 
angiotensin II may bind to the AT2 receptor instead of AT1. Signaling of Ang-(1-7) and Ang-(1-
9) as well as AT2 receptor activation have anti-oxidative and anti-fibrotic effects that may 
contribute to renoprotection in patients under dual treatment with SGLT2 and RAS blockers74,75. 
 
Podocyte Damage 
Podocytes play a key role in the pathogenesis of albuminuria; therefore, there is increasing interest 
on potential mechanism/s whereby SGLT2i may affect this cell type. A cross talk may occur 
between PT cells and podocytes. For instance, downregulation of SIRT1 in PT, causing reduced 
NAD production, induces both podocyte damage and albuminuria in experimental diabetes76. Of 
interest, tubular SIRT1 downregulation in db/db mice is mediated by enhanced PT glucose entry 
through SGLT2 followed by SGLT2 overexpression77.  
Although SGLT2 is not present within the glomeruli in normal conditions, SGLT2 is expressed 
by podocytes in a non-diabetic model of proteinuric glomerulopathy and dapagliflozin treatment 
ameliorated albuminuria, glomerular lesions, and podocyte dysfunction/loss in this model, 
suggesting a functional role of SGLT2 in podocytes63.  
 
SGLT2 inhibition and renal/genital side effects 
Treatment with SGLT2i enhances the risk of genital mycotic infections, particularly in women. 
By contrast, an increased risk of urinary tract infections was not found in CVOT with SGLT2i30-
32. Volume depletion may occur as a consequence of both osmotic diuresis and natriuresis. Volume 
depletion-related events did not differ in patients treated with either empagliflozin or placebo in 
the EMPA-REG, while a higher rate of volume depletion was observed in CKD patients treated 
with the highest canagliflozin dose in phase III clinical studies30,78. Volume depletion together 
with impaired auto-regulation of renal hemodynamics may enhance the likelihood of acute kidney 
injury (AKI). Neither CVOT with SGLT2i, nor real-world data showed an increased risk of AKI 
and AKI events were even reduced in the EMPA-REG30,79. However, SGLT2 inhibition should be 
used with caution in hemodynamic unstable patients or in combination with medications that may 
induce AKI and the FDA has requested to include AKI among the SGLT2i potential side effects 
following an excess of acute renal failure adverse reports80. In the CANVAS Program 
canagliflozin increased the risk of both overall bone fractures and lower limb amputations, though 
the latter was not confirmed in real life studies and experimental animals31,81,82. Whether this is a 
real and drug-specific effect remains unclear. Despite these adverse events do not directly involve 
the kidney, they are relevant to DN as mineral bone disorders complicate CKD and patients with 
DN have a high risk and prevalence of peripheral vascular disease. 
 
Conclusions and future perspectives  
In conclusion, there is emerging evidence that SGLT2i have an anti-proteinuric and renoprotective 
activity independent of the presence or absence of established CV disease. This benefit appears a 
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class effect and it is also observed in patients who are already under treatment with RAS inhibitors. 
This raises hope that dual RAS and SGLT2 blockade may represent a new therapy for DN, filling 
unmet needs for care and effectively tackling the cardio-renal vicious cycle.  
However, properly powered and dedicated studies are needed to clarify SGLT2i role in DN. There 
is thus great interest for ongoing clinical trials (Table 3) that will test the efficacy of SGLT2i on 
primary renal outcomes in people with established DN. In this regard it is noteworthy that the 
CREDENCE trial, designed to test the effect of canagliflozin compared to standard care in DM2 
patients with established DN78, was stopped early on July 2018 based on the achievement of pre-
specified efficacy criteria for the primary composite of doubling of serum creatinine, ESRD, and 
renal or CV death. The DAPA-CKD and the EMPA-KIDNEY trials will also clarify if SGLT2i 
may have renal benefits in other kidney diseases as they have enrolled non-diabetic patients with 
CKD and they are powered to show a renal benefit in this subgroup. Results from these trials have 
thus the potential to extend SGLT2i application beyond DN. 
A recent consensus report by the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) recommends considering the use of SGLT2i as add-
on therapy to metformin in DM2 patients with CKD with or without CVD83. Although, SGLT2i 
are currently not recommended in patients with reduced renal function, the beneficial effect of 
SGLT2i on BP and both CV and renal outcomes are retained in patients with reduced eGFR. Re-
evaluating current limitations on SGLT2i use in patients with CKD would allow more individuals 
to benefit from SGLT2 inhibition. Notably, SGLT2i may also be advantageous in the treatment of 
non-albuminuric DN, in which specific therapies are still lacking.  
Although our knowledge of SGLT2i mechanisms of renoprotection is gradually improving, basic 
science research is still left behind and we need to undertake a reverse “bedside to bench” approach 
to explain mechanistically exciting data coming from clinical trials.  
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Figure 1. Effects of SGLT2 inhibition on primary prevention, progression, and regression of 
albuminuria in the EMPA-REG OUTCOME trial and the CANVAS Program. HR (95% CI) 
are shown in red. 
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Figure 2. Renal outcomes in the EMPA-REG OUTCOME (EMPA), CANVAS Program 
(CANVAS) and DERIVE-TIMI 58 (DERIVE) trials. Data are expressed as incidence per 1000 
patient-year in SGLT2i-treated (red bars: composite end-point, blue bars: progression, brown bars: 
ESRD) and placebo-treated patients (white bars). HR (95% CI) values are also reported. On the x-
axis it is specified: end-point definition, type of variable (post-hoc, secondary, exploratory) and 
whether analyses were based on either single or confirmed measurements. Comparison should be 
taken with caution because of differences in both study design and recruited subjects. ESRD: end-
stage renal disease; dSCr: doubling of serum creatinine; eGFR: estimated glomerular filtration rate 
(value expressed as ml/min/1.73 m2), RRT: renal replacement therapy.  
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Figure 3. Mechanisms implicated in renal protective effect of SGLT2 inhibition  
(A) In diabetes, both hyperglycemia and systemic hypertension play a key role in the pathogenesis 
of the glomerular injury and enhanced SGLT2-mediated glucose/Na+ reabsorption in the proximal 
tubule (PT) contribute to both. The reduced delivery of Na+ to the macula densa diminishes 
adenosine production and leads to afferent arteriole vasodilation. Deactivation of the tubular-
glomerular feed back (TGF) together with renin-angiotensin-system (RAS)-mediated efferent 
arteriole vasoconstriction results in glomerular capillary hypertension (PGC) that induces 
hyperfiltration and glomerular volume expansion with cyclic stretching and damage of glomerular 
cells. Enhanced PT glucose reabsorption may cause inflammation, oxidative stress with reactive 
oxygen species (ROS) production, and fibrosis leading to tubule-interstitial injury and possibly 
contributing to podocyte damage via PT-podocyte cross talk. Finally, increased oxygen 
consumption in the renal cortex may contribute to renal fibrosis by inducing hypoxia and trans-
differentiation of erythropoietin-producing fibroblasts (FBEPO) in profibrotic myofibroblasts 
(MyoFb). (B) In patients treated with SGLT2 inhibitors (SGLT2i), enhanced glycosuria, 
natriuresis, and osmotic diuresis lower both blood glucose and blood pressure levels. By inhibiting 
Na+ reabsorption at both SGLT2 and Na+/H+ exchanger-3 (NHE3) level, SGLT2i reactivate the 
TGF with lowering of PGC and reduced glomerular cell stretching. Reduced glucose reabsorption 
diminishes local glucotoxicity. Amelioration of renal cortex hypoxia allows myofibroblasts re-
differentiation in EPO-producing cells reducing renal fibrosis and enhancing EPO production.  
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Table 1: Cardiovascular Outcome Trials with SGLT2i: Design and Baseline Characteristics 
 
 EMPA-REG 
OUTCOME 
CANVAS  
Program 
DECLARE-TIMI 58 
Randomized patients (n°) 7,020 10,142 17,160 
Active treatment  Empagliflozin 10 
or 25 mg 
Canagliflozin 100 
or 300 mg 
Dapagliflozin 10 mg 
Follow-up (median, yrs) 3.1 2.4 4.2 
Main inclusion criteria     
Age (yrs) 18 30 40 
HbA1c (%) 7-10 7-10.5 6.5-12.0 
Body mass index (Kg/m2) 45 - - 
eGFR (ml/min/1.73m2)  30  30  60 
Cardiovascular disease or 
cardiovascular risk factors 
CVD CVD or age >50 
and 2 RF  
CVD or age 55 (M) 
60 (F) and 1 RF 
Baseline parameters    
Male (%) 72 66 63 
Age (mean, yrs) 63 63 64 
HbA1c (mean, %) 8.1 8.2 8.3 
Systolic BP (mmHg) 135 137 135 
CV Status (%)    
Secondary prevention  99 66 41 
Primary prevention  1 34  59 
UACR (%)    
<30 mg/g  60 70 70 
30-300 mg/g  29 23 23 
>300 mg/g  11 7 7 
CKD stage (%)    
>60 ml/min/1.73m2 74 80 93 
45-59 ml/min/1.73m2 18 15 7 
<45 ml/min/1.73m2 8 5 0 
eGFR (mean, ml/min/1.73m2) 74.2 76.5 85.2 
RAS blocker therapy (%) 80 80 81 
RF: cardiovascular risk factors; CV: cardiovascular; M: male; F: female; BP: blood pressure; UACR: urinary albumin 
excretion rate; CKD: chronic kidney disease; RAS: renin angiotensin system; eGFR: estimated glomerular filtration rate. 
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Table 2: SGLT2 inhibitors in Experimental Diabetic Nephropathy 
Active 
Treatment 
Animal Model Study Design Study 
Duration 
Functional and 
structural effects 
Mechanisms 
Empagliflozin84 Type 1 DM  
(eNOS-KO STZ mice) 
Empaglifozin 
10 mg/kg/day vs. 
insulin 
19 weeks = Albuminuria 
= Glomerulosclerosis 
= Tubular atrophy 
 
Empagliflozin85 Type 2 DM  
(db/db mice)  
 
Empaglifozin 
10 mg/kg/day vs. 
metformin 
10 weeks = Albuminuria  
= Glomerulosclerosis 
= Kidney growth 
 Fibrosis (fibronectin 
TGF-) 
Dapaglifozin86 Type 2 DM  
(OLEFT rats) 
 
Dapaglifozin 
1 mg/kg/day 
vs. voglibose 
12 weeks  Albuminuria 
 Mesangial  
 Interstitial fibrosis 
 RAS activation 
 Oxidative stress  
 Inflammation  
Dapaglifozin87 Type 1 DM  
(Akita mice) 
 
Dapaglifozin 
1 mg/kg/day vs. 
insulin 
12 weeks  Albuminuria  
 Interstitial fibrosis 
 Interstitial 
inflammation  
 Fibrosis (TGF-1) 
 Oxidative stress  
Dapaglifozin88 Type 2 DM  
(db/db mice)  
 
Dapaglifozin 
2 mg/kg/day vs. 
pioglitazone 
9 weeks = Albuminuria 
= Mesangial 
Expansion 
= Foot process width 
 
Luseoglifozin89 Type 1 DM and 
hypertension  
(STZ-Dahl Salt-sensitive rats) 
Luseoglifozin 
10 mg/kg/day vs. 
insulin 
8 weeks = Albuminuria 
= Hyperfiltration 
= Renal injury 
 
Luseoglifozin90 Type 2 DM   
(T2DN rats) 
Luseoglifozin 
10 mg/kg food vs. 
insulin 
12 weeks  eGFR decline 
 Glomerulosclerosis, 
 Renal fibrosis  
 Nephrin excretion 
Ipraglifozin91 Type 2 DM   
(BTBR ob/ob mice) 
Ipraglifozin 
4 mg/kg/day vs. 
30% calorie 
restriction 
18 weeks  Albuminuria 
 Hyperfiltration 
 Mesangial 
expansion 
 TCA cycle 
 Oxidative stress 
DM: diabetes; RAS: renin angiotensin system; TCA: tricarboxylic acid cycle; eGFR: glomerular filtration rate; TGF-β1: transforming 
growth factor-β1; KO: knockout; STZ: streptozotocin. 
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Table 3: Major Ongoing SGLT2 Inhibitor Trials with Renal Outcomes 
Study Name EMPA- KIDNEY CREDENCE DAPA- CKD VERTIS CV 
Registration 
Number 
NCT03594110 NCT02065791 NCT03036150 NCT01986881 
Intervention 
Empaglifozin vs. 
placebo 
Canaglifozin 100 
mg vs. placebo 
Dapaglifozin 5 and 
10 mg vs. placebo 
Ertuglifozin 5 and 
15 mg vs. placebo 
N° patients 5,000 (estimated) 4,401 4,000 (estimated) 8,000 (estimated) 
Study 
Population 
DM2 and non-DM2 
with CKD 
DM2 with CKD 
and high CV risk 
DM2 and non-DM2 
with CKD and high 
CV risk 
DM2 with CVD 
Renal 
Inclusion 
Criteria 
eGFR 20-44 
mL/min/1.73m2 or  
eGFR <90 
mL/min/1.73m2 with 
UACR ≥200 mg/g 
eGFR 30-90 
mL/min/1.73m2 
with UACR 300-
5000 mg/g 
eGFR 25-75 
mL/min/1.73m2 with 
UACR 200-5000 
mg/g 
eGFR 30 
mL/min/1.73m2 
Estimated 
FU 
Duration  
3.1 yrs 5.5 yrs 4 yrs 6.1 yrs 
Primary 
Composite 
Outcomes 
CKD progression 
(≥40% eGFR, 
ESRD1, eGFR <10 
mL/min/1.73m2, renal 
death) or CV death 
ESRD2, 
dSCr, or 
CV or renal death 
ESRD2,  
≥50% eGFR or  
CV or renal death 
MACE 
Secondary 
Renal 
Outcomes 
CKD progression, 
CV death or ESRD 
Renal composite 
outcome (ESRD2, 
dSCr, or renal 
death) 
Individual 
components of the 
primary outcome 
Renal composite 
outcome (dSCr, 
RRT, or renal death) 
Estimated 
Completion 
Date 
June 2022 June 20193 November 2020 September 2019 
1ESRD initiation of maintenance dialysis or receipt of a kidney transplant 
2ESRD initiation of maintenance dialysis or receipt of a kidney transplant or sustained <15 mL/min/1.73 m2 
3 The trial was stopped study early on July 2018 based on the achievement of pre-specified efficacy criteria for the primary 
composite 
DM2: type 2 diabetes; CVD: cardiovascular disease; CV: cardiovascular; FU: follow-up; eGFR: estimated glomerular filtration 
rate; ESRD; end-stage renal disease; CKD: chronic kidney disease; MACE: major advanced cardiovascular events; dSCr: 
doubling of serum creatinine from baseline; UACR: urinary albumin excretion. EMPA- KIDNEY: The Study of Heart 
and Kidney Protection With Empagliflozin CREDENCE: Evaluation of the Effects of Canagliflozin on Renal and 
Cardiovascular Outcomes in Participants With Diabetic Nephropathy; DAPA-CKD: A Study to Evaluate the 
Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney 
Disease; VERTIS CV: Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus 
Participants With Vascular Disease. 
 
 
 
 
